Hydroxychloroquine/lopinavir/ritonavir/peginterferonDiarrhoea and off-label treatment: 4 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1907卷 / 1期

关键词：

D O I：

10.1007/s40278-022-15500-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：241 / 241

相关论文

共 50 条

[21] Lopinavir/ritonavirAcute kidney injury following off-label use: 8 case reports
Reactions Weekly, 2020, 1834 (1) : 154 - 154
[22] Mycophenolate-mofetilLack of efficacy with off-label treatment: 4 case reports
Reactions Weekly, 2022, 1913 (1) : 350 - 350
[23] Ceftriaxone/ertapenemVarious toxicities following off-label treatment: 4 case reports
Reactions Weekly, 2019, 1766 (1) : 97 - 97
[24] Lopinavir/ritonavir/tocilizumabMyositis, Staphylococcus epidermidis bacteraemia, hepatitis and ventilator-associated pneumonia following off-label use: 3 case reports
Reactions Weekly, 2020, 1822 (1) : 190 - 190
[25] Hydroxychloroquine and "off-label" utilization in the treatment of oral conditions
Brown, Ronald
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2020, 129 (06): : 643 - 644
[26] ValganciclovirNeutropenia following off-label treatment: 6 case reports
Reactions Weekly, 2021, 1847 (1) : 427 - 427
[27] DupilumabHypereosinophilia during off-label treatment: 16 case reports
Reactions Weekly, 2020, 1816 (1) : 137 - 137
[28] RituximabHypogammaglobulinaemia follwing off-label treatment: 3 case reports
Reactions Weekly, 2019, 1746 (1) : 176 - 176
[29] MogamulizumabRash following off-label use: 4 case reports
Reactions Weekly, 2023, 1984 (1) : 345 - 345
[30] RanibizumabSubconjunctival haemorrhage and off-label use: 4 case reports
Reactions Weekly, 2020, 1788 (1) : 200 - 200

← 1 2 3 4 5 →